Sir, A pharmacological blockade of the renin-angiotensinaldosterone system (RAAS) constitutes a cornerstone strategy for inhibiting progression of chronic nephropathies. In a recent NDT issue, Tomas Berl [1] discussed the improvements in renal outcome associated with maximal RAAS inhibition achieved using combined therapies that included angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), renin inhibitors and mineralocorticoid receptor antagonists. Alternatively, patients were administered ACEI or ARB at doses highly exceeding those approved for blood pressure control. Here, we elaborate on this very interesting discussion by reporting that a double RAAS blockade with high-dose ACEI attenuates oxidative stress phenomena in patients with chronic kidney disease (CKD) .
In an open, randomized, cross-over study, 18 white adult patients (11 men and 7 women; mean age: 42 years) with nondiabetic proteinuric CKD were evaluated to test the hypothesis that high-dose ACEI (10 mg cilazapril) combined with standard ARB (telmisartan) therapy increases nephroprotection by lowering the level of potentially nephrotoxic, oxidative stress-dependent products. The trial treatment was based on 80-mg telmisartan therapy combined with either 5 mg cilazapril or 10 mg cilazapril for 2 months of the study; the alternative being used for the next 2 months. A commercial ELISA kit (Cayman Chemical Co., USA) was then used to measure the urinary excretion of 15-F 2t -isoprostane in the treated patients. 15-F 2t -isoprostane is accepted as a reliable and sensitive marker of oxidative stress in the human body [2.] It was found that the higher dose cilazapril treatment significantly reduced urinary levels of 15-F 2t -isoprostane relative to the control group (ANOVA P = 0.008; post hoc P = 0.044) with no changes observed in systemic blood pressure, serum creatinine or potassium levels (Table 1) . This finding may be of clinical relevance, as 15-F 2t -isoprostane has biological activity as a potent renal vasocon- 
Meningococcal vaccination and chronic kidney disease
Sir, We read with great interest the editorial review about vaccination and chronic kidney disease by Janus et al [1] . Although this article is focused on end-stage renal disease patients, we think that it is possible to mention the meningococcal vaccine.
This immunization is usually recommended for people exposed to a case of severe meningococcal infection, or for people travelling in endemic zones (sub-Saharan meningitis belt) in close contact with the local population. In some countries, this vaccine is incorporated in national vaccination programmes [2] .
A few years ago, a risk of relapse of nephrotic syndrome was signalled, after meningococcal C conjugate vaccine [3] . However, that has been invalidated by a more recent study where no link was found between vaccination and a risk of relapse [4] .
Thus the use of this vaccine, when necessary, can be recommended.
However, there is a lack of data upon the degree of the immune response to this kind of vaccine in immunosuppressed patients. For asplenic individuals, for example, a double dose of vaccine has been proposed [5] . (Table 1) .
The present observation suggests that (1) cinacalcet can reduce the size of PTG, and that (2) the sensitivity of the lobes of the PTG to cinacalcet can differ within a single patient. Regarding the first point, Mizobuchi et al. have reported that a high concentration of calcimimetic agent induces apoptosis in cultured hyperplastic parathyroid cells [2] . Regarding the second point, Kawata et al. have reported that the suppressive effect of cinacalcet on PTH secretion correlates negatively with the degree of calcium-sensing receptor expression in a rat model [3] .
To our knowledge, this is the first report showing that cinacalcet can reduce the size of the PTG in a clinical setting. Considering the case report by Lazar and Stankus that cinacalcet can induce hungry-bone syndrome, as does parathyroidectomy [4] , treatment with cinacalcet might be a curative treatment for secondary hyperparathyroidism, as is parathyroidectomy.
